Status:
TERMINATED
Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.
Lead Sponsor:
Erasme University Hospital
Conditions:
Type 2 Diabetes
Incretinomimetics
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Incretinomimetics and inhibitors of dipeptidyl peptidase-4 (DPP-4) are new treatments for diabetes. Previous retrospective studies have shown that these treatments induced an increase in pancreatic ma...
Detailed Description
The incretinomimetics and the inhibitors of dipeptidyl peptidase-4 (DPP-4) are new treatments for diabetes. The incretinomimetics are analogs of Glucagon Like Peptide 1 (GLP-1), secreted from endocrin...
Eligibility Criteria
Inclusion
- Type 2 diabetes inadequately controlled or intolerant to metformin
- Obtaining informed consent
- Aged between 18 and 70 years
- BMI between 20 and 45 kg / m²
Exclusion
- Contraindication to nuclear magnetic resonance (NMR):
- Carrying a metallic foreign body (pacemaker, valve, intraocular equipment, clips)
- Allergy to Gadolinium / Secretin
- Pregnancy or breastfeeding
- Contraindication to treatment with incretinomimetic:
- Hypersensitivity to the active substance or to any of the excipients
- Severe Gastroparesis
- Severe renal impairment
- History of Surgery (gastroduodenal, pancreatic or ileocecal)
- Presence or history of pancreatic disease
- Active alcoholism
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 13 2023
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT02244164
Start Date
October 1 2014
End Date
February 13 2023
Last Update
February 16 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gastroenterology Department Erasme Hospital
Brussels, Belgium, 1070